Characterizing immunocompetent models of PSMA plus prostate cancer to investigate [225Ac]Ac-PSMA-617 efficacy in mice

被引：0
|
作者：
Taddio, Marco [1 ]
Rodriguez, Arely Perez [2 ]
Azrour, Ines [1 ]
Richard, Mathis [1 ]
Vilangattil, Meryl [1 ]
Jeanjean, Pauline [3 ]
Besserer-Offroy, Elie [4 ]
Carlucci, Giuseppe [1 ]
Czernin, Johannes [1 ]
Mona, Christine [1 ]
机构：
[1] Univ Calif Los Angeles, Ahmanson Translat Theranost Div, Pharmacol, Los Angeles, CA USA
[2] UCLA, Ahmanson Translat Theranost Div, Pharmacol, Los Angeles, CA USA
[3] UCLA, Los Angeles, CA USA
[4] Univ Calif Los Angeles, Ahmanson Translat Theranost Div, Los Angeles, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P1216
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study
    Sanjana Ballal
    Madhav P Yadav
    Swayamjeet Satapathy
    Shobhana Raju
    Madhavi Tripathi
    Nishikant A Damle
    Ranjit K Sahoo
    Chandrasekhar Bal
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 3777 - 3789
  • [22] Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy
    Rosar, Florian
    Hau, Fabian
    Bartholoma, Mark
    Maus, Stephan
    Stemler, Tobias
    Linxweiler, Johannes
    Ezziddin, Samer
    Khreish, Fadi
    THERANOSTICS, 2021, 11 (09): : 4050 - 4060
  • [23] Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
    Czernin, Johannes
    Current, Kyle
    Mona, Christine E.
    Nyiranshuti, Lea
    Hikmat, Firas
    Radu, Caius G.
    Luckerath, Katharina
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (02) : 228 - 231
  • [24] Immune-checkpoint blockade enhances225Ac-PSMA617 efficacy in a mouse model of prostate cancer
    Lueckerath, K.
    Current, K.
    Mona, C. E.
    Nyiranshut, L.
    Hikmat, F.
    Radu, C. G.
    Czernin, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S161 - S162
  • [25] Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
    Tauber, R. L.
    Feuerecker, B.
    Knorr, K.
    Beheshti, A.
    Seidl, C.
    D'Alessandria, C.
    Bruchertseifer, F.
    Retz, M.
    Gschwend, J. E.
    Weber, W.
    Morgenstern, A.
    Eiber, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] 225Ac-PSMA-617 Targeted Therapy in MCRPC
    Pappas, Virginia
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (10) : 26N - 26N
  • [27] Outcomes and Molecular Profiling with 225Ac-PSMA-617
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (03) : 19N - 19N
  • [28] Synthesis of 225Ac-PSMA-617 for Preclinical Use
    Dumond, Alexandra Rae Sowa
    Rodnick, Melissa Elizabeth
    Piert, Morand Ruediger
    Scott, Peter James Henry
    CURRENT RADIOPHARMACEUTICALS, 2022, 15 (02) : 96 - 103
  • [29] Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617
    Sathekge, Mike M.
    Bruchertseifer, Frank
    Lawal, Ismaheel O.
    Vorster, Mariza
    Knoesen, Otto
    Lengana, Thabo
    Boshomane, Tebatso G.
    Mokoala, Kgomotso K.
    Morgenstern, Alfred
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (08) : 1756 - 1757
  • [30] Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617
    Mike M. Sathekge
    Frank Bruchertseifer
    Ismaheel O. Lawal
    Mariza Vorster
    Otto Knoesen
    Thabo Lengana
    Tebatso G. Boshomane
    Kgomotso K. Mokoala
    Alfred Morgenstern
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1756 - 1757
12345